Carboxamidine derivatives and their use in the treatment of vascular diseases

1. A compound of formula III

wherein R 1 and R 2 are independently hydrogen, straight chained C 1-6 alkyl group optionally substituted with a phenyl group, branched C 1-6 alkyl group optionally substituted with a phenyl group, or R 1 and R 2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein said heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;

A is a 5-6 membered N-containing heteroaromatic ring having a N-oxide structure on the nitrogen heteroatom;

n is 0, 1, or 2;

z is 0 or 1;

or a stereoisomer or salt thereof.

2. The compound according to claim 1 , wherein the compound is 5,6-dihydro-5-[(1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

3. The compound according to claim 2 , wherein the compound is (+)-5,6-dihydro-5-[(1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

4. The compound according to claim 1 , wherein the compound is 5,6-dihydro-5-[(1-oxido-1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

5. A pharmaceutical composition comprising a compound of formula III as defined in claim 1 and a pharmaceutically acceptable carrier.

6. A compound of formula III

wherein R 1 and R 2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups;

A is a phenyl group optionally substituted with one or more C 1-4 alkyl, C 1-4 haloalkyl, nitro, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein the nitrogen heteroatom optionally has a N-oxide structure;

n is 0, 1, or 2;

z is 0 or 1;

or a stereoisomer or salt thereof.

7. The compound according to claim 6 , wherein the compound is 5,6-dihydro-5-[(4-benzyl-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

8. The compound according to claim 6 , wherein the compound is 5,6-dihydro-5-[(2-oxo-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

9. The compound according to claim 6 , wherein the compound is 5,6-dihydro-5-[(4-hydroxy-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

10. A pharmaceutical composition comprising a compound of formula III as defined in claim 6 and a pharmaceutically acceptable carrier.